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We describe a case of anaphylactic reaction in a 46-year-old female post application of decongestant nose drops
containing benzalkonium chloride (BAC). With some latency, the patient complained of cough, dyspnea, sensation
of heat, croakiness and pruritus. Since she showed all of these symptoms, typical of an anaphylactic reaction, we
proceeded some weeks later with a prick test with solutions containing BAC, a cationic surfactant commonly used
as an antibacterial preservative in many medical solutions. The prick test was positive, confirming the assumption of
a hypersensitive reaction to BAC.
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This is the first case described in the literature of an
immediate-type (type I) allergic reaction to nose drops
containing benzalkonium chloride. Benzalkonium chlor-
ide (N-alkyl-N-benzyl-N,N-dimethyl ammonium chloride)
is a quaternary ammonium compound used, for instance,
as a preservative agent in topical medications (eye and
nose drops).Case presentation
A 46-year-old female patient presented in our outpatient
department with an existing nasal respiration obstruction
she had been experiencing for about 3 months with right-
side preponderance, severe right-side facial pain and a
subjectively reduced sense of smell. Surgical restoration of
the right maxillary sinus was considered due to the inef-
fectiveness of the oral antibiotic and steroid treatments
carried out to date. Six years earlier, the patient had under-
gone an endonasal septal deviation pansinus operation
with septoplasty in the treatment of chronic ethmoid and
maxillary sinusitis. In the years between this procedure
and recurrence of the symptoms described above, the
patient was otherwise free of symptoms, undergoing only
various dental procedures.* Correspondence: Elke.mezger@uk-erlangen.de
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reproduction in any medium, provided the orExamination and findings
A rhinoscopic examination initially revealed nearly
complete nasal obstruction by an inflammatory hyper-
plasia of the inferior turbinate on the right side and un-
remarkable findings on the left side. Further endoscopic
examination revealed inflammatory narrowing of the
right middle nasal meatus, with plentiful putrid secretion
and polypoid mucosa in the area of the right ethmoid
bone. The left middle nasal meatus was open and the
septum position was median postoperatively. The
remaining ENT findings were normal, in keeping with
the patient's age. The findings from the computed tom-
ography of the nasal sinuses done one week previously
were of right-side sinusitis with a broad area of mucosal
swelling around the fenestrated maxillary sinus as well
as of the nasal cavity and the right-side portion of the
sphenoid sinus and ethmoid cells. The images showed
open nasal sinuses on the left side. The results of a prick
test for fungal allergens performed in 2004 prick were a
double positive reaction to Aspergillus fumigatus and a
simple positive reaction to Cladosporium herbarum.
There is otherwise no known history of further allergies.Diagnostics
A rhinomanometric examination confirmed the right-
side nasal obstruction, with normal findings for the left
side. The olfactory test result was normosmic. Diagnos-
tics continued with mucosal detumescence by means of
spray application of OtrivenW (from Novartis, containingLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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pirate the putrid secretion and explore the maxillary
sinus. Chunky gray material was removed that suggested
an aspergilloma. However, after about 20 to 30 min, the
patient then reported increasing massive bilateral ob-
struction of the nose and a strong sense of heat in the
head. She also complained of itching in the throat,
hoarseness, edematous swelling of the uvula and soft
palate, and vesicles on the posterior pharyngeal wall.
A synoptic analysis of the symptoms led us to suspect
an anaphylactic reaction to components of OtrivenW.
Therapy
Acute treatment of the anaphylactic reaction comprised
Soludecortin H (250 mg iv.), one ampoule of TavegilW
(clemastine fumarate), one ampoule of RaniticW (raniti-
dine), oxygen through a nasal tube (3 l/min) and volume
supplementation with JonosterilW infusions (1 l/hour).
The patient was hospitalized for monitoring.
Course
The patient's condition returned to normal within four
hours. She continued to receive nasal irrigation and a
nasal emulsion formulated in our hospital that contained
no preservatives whatever. It was possible to discharge
the patient to outpatient care after two days. After four
weeks she presented once again for an ENT monitoring
examination. At this time she was completely free of
symptoms, i.e. was not experiencing nasal obstruction
and/or facial pain. The endoscopic examination showed
an unremarkable lower and middle nasal turbinate on
the right side, an unobstructed view into the maxillary
sinus ostium and free ascension to the frontal sinus.
Six weeks after the anaphylactic event, a prick test was
carried out with three different concentrations of ben-
zalkonium chloride (0.01% solution, 0.1% solution, 0.5%
solution, each dissolved in H2O). 0.1% elicited a mild re-
action (simple positive), 0.5% a very strong reaction
(triple positive), including negative control with NaCl
and positive control with histamine hydrochloride
(10 mg/ml). A prick test was conducted with the same
solutions in a control group of 15 volunteers, with nega-
tive results in all cases. The suspected diagnosis of al-
lergy to benzalkonium chloride was therefore confirmed.
Discussion
This is the first case described in the literature of an
immediate-type (type I) allergic reaction to nose drops
containing benzalkonium chloride. Benzalkonium chlor-
ide (N-alkyl-N-benzyl-N,N-dimethyl ammonium chloride)
is a quaternary ammonium compound used, for instance,
as a preservative agent in topical medications (eye and
nose drops). It is also used in disinfectants, medicinal
gargle solutions, throat lozenges, adhesive bandages, asan algicide in swimming pools and in medicinal cos-
metics; it is also used as an industrial chemical in dye
synthesis and metallurgy, in agriculture and the textile
industry. Numerous cases of allergic reactions to this
quaternary ammonium compound have been reported
[1], also in the context of type I reactions to antiasth-
matic sprays [2], eye drops [3] and ear drops [4] con-
taining benzalkonium chloride. The symptoms ranged
from paradoxical bronchoconstriction to anaphylactic
reaction and angioneurotic edema [3]. Occurrence of
toxic contact dermatitis in a type IV reaction [5] has
also been described. A property causing direct damage
to cilia has also been reported, which must be kept in
mind above all when the agents are used on mucosa
with ciliated epithelia such as those of the nose or
upper respiratory tract [6]. This is discussed mainly in
connection with a drug rhinitis, which is by definition
not caused by an allergy, but rather by a directly harm-
ful effect of the agent that manifests after regular use
[7]. It has, however, been demonstrated in various ani-
mal studies that benzalkonium chloride results in
increases of total IgE and IgG1 in the blood, mediated
by TH2 lymphocytes, and thus causes sensitization [8].
It can therefore be assumed that the reaction to ben-
zalkonium chloride was presumably an IgE-mediated,
type 1 reaction, although non-specific histamine release
from mast cells is also being discussed [2]. The occur-
rence of toxic contact dermatitis associated with ben-
zalkonium chloride is presumably due to activation of
allergen-specific cytotoxic T cells. Various diagnostic
approaches are available to confirm a benzalkonium
chloride allergy. Determination of antibodies, specifically
total IgE and specific IgE, is a method commonly prac-
ticed in allergy diagnostics. Application of this method
is, however, not feasible in the case of benzalkonium
chloride since there is no specific IgE to benzalkonium
chloride. A rise in total IgE may indeed be indicative of
an atopic disposition, but it is not specific enough to
be used as a diagnostic tool, since it is not conclusive
and an allergy may also be present in the absence of an
increase. As described above, benzalkonium chloride
also leads to an increase of IgG1. Determination of this
antibody is not useful because it can be detected in sera
from both healthy and atopic individuals. It also merely
reflects exposure to an allergen. There is also the possi-
bility, for allergies associated with mast cells, of deter-
mining mast cell tryptase, whereby it is important to
determine the initial value as a basis for comparison,
which is often not possible. Secondary diagnostics also
include the basophil stimulation test, which can be
interpreted as an indirect measure of cell-bound IgE
and, when other stimuli are applied, is also indicative of
IgE-independent reactivity of the leukocytes involved.
Implementation of this test requires a concentration of
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certain degree. Since benzalkonium chloride can also
cause type IV reactions, a further method that can be
applied is the lymphocyte transformation test, in which
lymphocyte cultures are exposed to antigen-presenting
cells and the suspected allergen, whereby incorporation
of H3-thymidine serves as the measure of lymphocyte
transformation. This test cannot, however, distinguish
between a physiological response to an antigen and an
allergic reaction and also poses high technical require-
ments. Skin tests such as the prick and intracutaneous
tests are well-established in allergy diagnostics and are
particularly well-suited to identify type I reactions. We
also decided to employ these methods, to which end
we created a test series of different solutions containing
benzalkonium chloride in different concentrations. We
were able to confirm the allergy in this patient by
employing this method.Conclusions
Medical application of decongestant nose drops should
also take into consideration the rare, but possible, allergic
reaction to benzalkonium chloride as described above.
Questions about previous allergic reactions or symptoms
in reaction to similar drugs must therefore be included in
the medical history interview and, if there is any doubt,
clarification should be based on a prior allergy test. In case
of a positive result, patients must be carefully informed
and instructed concerning strict avoidance of substances
containing the preservative agent and the need to contact a
physician without delay if allergic symptoms occur. A fur-
ther alternative for patients with rhinitis symptoms is use
of decongestant nose drops that contain no preservatives.Consent
We state that the patient has given her consent for the
Case report to be published.
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